Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for reading IBOX
Hey guys I'm still here, always pretty busy,.... updated the "Intro" a few days ago..
I have a few minutes left for a discussion....11.54pm here
Former ‘King of Biotech’ settles with SEC
By Bernard Vaughan
NEW YORK | Thu Aug 22, 2013 8:18pm EDT
(Reuters) - An investor formerly known as the "King of Biotech" has reached a settlement with the U.S. Securities and Exchange Commission over a market manipulation scheme, according to court documents filed on Thursday.
David Blech, who earned the nickname as a founder of companies and a major investor in the biotechnology sector, agreed to pay $1.03 million in disgorgement and interest for the scheme.
In 2012 the SEC had accused Blech of buying and selling significant amounts of stock in two biopharmaceutical companies, Pluristem Therapeutics Inc and Intellect Neurosciences Inc through more than 50 brokerage accounts he established in the names of family and friends in order to create an artificial appearance of activity in the stocks.
The SEC complaint further accused Blech, who had already been convicted of securities fraud in 1998, of selling investments for biopharmaceutical companies despite being barred from acting as a broker-dealer. It also accused him and his wife, Margaret Chassman, of violating federal securities laws by making unregistered sales of securities and failing to disclose their transactions in brokerage accounts.
Chassman agreed to pay close to $550,000 in disgorgement, interest and a civil penalty, according to the settlement.
The settlement was approved by Magistrate Judge Sarah Netburn in Manhattan federal court.
"He's pleased to be putting this episode behind him," Roland Riopelle, a lawyer for Blech, said on Thursday.
A lawyer for Chassman declined to comment.
In May, Blech was sentenced to four years in prison after pleading guilty in a related criminal case to stock manipulation stemming from his trades in Pluristem and Intellect.
The case is USA v David Blech, U.S. District Court, Southern District of New York, No. 12-cr-00372.
(Reporting by Bernard Vaughan; Editing by Chris Gallagher)
http://www.reuters.com/article/2013/08/23/us-biotech-fraud-sentence-idUSBRE97M00920130823
HE HAD THE SAME ACCOUNTS HERE!!
Former ‘King of Biotech’ settles with SEC
By Bernard Vaughan
NEW YORK | Thu Aug 22, 2013 8:18pm EDT
(Reuters) - An investor formerly known as the "King of Biotech" has reached a settlement with the U.S. Securities and Exchange Commission over a market manipulation scheme, according to court documents filed on Thursday.
David Blech, who earned the nickname as a founder of companies and a major investor in the biotechnology sector, agreed to pay $1.03 million in disgorgement and interest for the scheme.
In 2012 the SEC had accused Blech of buying and selling significant amounts of stock in two biopharmaceutical companies, Pluristem Therapeutics Inc and Intellect Neurosciences Inc through more than 50 brokerage accounts he established in the names of family and friends in order to create an artificial appearance of activity in the stocks.
The SEC complaint further accused Blech, who had already been convicted of securities fraud in 1998, of selling investments for biopharmaceutical companies despite being barred from acting as a broker-dealer. It also accused him and his wife, Margaret Chassman, of violating federal securities laws by making unregistered sales of securities and failing to disclose their transactions in brokerage accounts.
Chassman agreed to pay close to $550,000 in disgorgement, interest and a civil penalty, according to the settlement.
The settlement was approved by Magistrate Judge Sarah Netburn in Manhattan federal court.
"He's pleased to be putting this episode behind him," Roland Riopelle, a lawyer for Blech, said on Thursday.
A lawyer for Chassman declined to comment.
In May, Blech was sentenced to four years in prison after pleading guilty in a related criminal case to stock manipulation stemming from his trades in Pluristem and Intellect.
The case is USA v David Blech, U.S. District Court, Southern District of New York, No. 12-cr-00372.
(Reporting by Bernard Vaughan; Editing by Chris Gallagher)
http://www.reuters.com/article/2013/08/23/us-biotech-fraud-sentence-idUSBRE97M00920130823
ILNS
Ponezumab status change from Recruiting to Not yet Recruiting 08/16/2013
http://www.clinicaltrials.gov/ct2/show/NCT01821118?term=ponezumab&rank=5
Look for history of changes
ILNS
Up we go!! ;)
Thanks for sharing tencoin
PFE - Ponezumab Studies
Rank Status Study
1 Completed Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 1 mg/kg; Biological: PF-04360365 3 mg/kg; Biological: PF-04360365 5 mg/kg; Biological: PF-04360365 10 mg/kg
2 Completed Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 0.1 mg/kg; Biological: PF-04360365 0.5 mg/kg; Biological: PF-04360365 1 mg/kg; Drug: Placebo; Biological: PF-04360365 3 mg/kg; Biological: PF-04360365 8.5 mg/kg
3 Completed Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 8.5 mg/kg; Drug: Placebo
4 Completed A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo
5 Recruiting Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Condition: Cerebral Amyloid Angiopathy
Interventions: Biological: Ponezumab; Other: placebo
6 Completed Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo
7 Completed A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 10 mg/kg; Biological: PF-04360365 7.5 mg/kg; Drug: placebo
8 Completed A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365; Drug: Placebo
http://clinicaltrials.gov/ct2/results?term=ponezumab&Search=Search
So we have 8 studies with ponezumab and the tech. based on ANTISENILIN platform. No one is interested in ILNS technology?
5 Recruiting Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Condition: Cerebral Amyloid Angiopathy
Interventions: Biological: Ponezumab; Other: placebo
Hey, sorry but i have to reduce my time here...(f....business)
Best regards from Austria!
Hold Strong all Longs!
TauC3, Laferla F
J Neurochem. 2013 May 15. doi: 10.1111/jnc.12305. [Epub ahead of print]
Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aß deposition and tau pathology in 3xTg-AD mice.
Rasool S, Martinez-Coria H, Wu JW, Laferla F, Glabe CG.
Source
Department of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
Abstract
Alzheimer's disease (AD) is a devastating disorder that is clinically characterized by a comprehensive cognitive decline. Accumulation of the amyloid-beta (Aß) peptide plays a pivotal role in the pathogenesis of AD. In AD, the conversion of Aß from a physiological soluble monomeric form into insoluble fibrillar conformation is an important event. The most toxic form of Aß is oligomers, which is the intermediate step during the conversion of monomeric form to fibrillar form. There are at least two types of oligomers: oligomers that are immunologically related to fibrils and those that are not. In transgenic AD animal models, both active and passive anti-Aß immunotherapies improve cognitive function and clear the parenchymal accumulation of amyloid plaques in the brain. In this report we studied effect of immunotherapy of two sequence-independent non-fibrillar oligomer specific monoclonal antibodies on the cognitive function, amyloid load and tau pathology in 3xTg-AD mice. Anti-oligomeric monoclonal antibodies significantly reduce the amyloid load and improve the cognition. The clearance of amyloid load was significantly correlated with reduced tau hyperphosphorylation and improvement in cognition. These results demonstrate that systemic immunotherapy using oligomer-specific monoclonal antibodies effectively attenuates behavioral and pathological impairments in 3xTg-AD mice. These findings demonstrate the potential of using oligomer specific monoclonal antibodies as a therapeutic approach to prevent and treat Alzheimer's disease.
© 2013 International Society for Neurochemistry.
http://www.ncbi.nlm.nih.gov/pubmed/23672786
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
This study is currently recruiting participants
ClinicalTrials.gov Identifier:
NCT01821118
First received: March 4, 2013
Last updated: July 22, 2013
Last verified: July 2013
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
Purpose
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aß40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain. Probable CAA may be defined as two or more hemorrhages in the brain cortex in individuals 55 years of age or older. This study will examine the study drug (PF-04360365) vs. placebo (saline) at 10 mg/kg - Day 1 and the maintenance dose of the study drug (PF-04360365) vs. placebo (saline) at 7.5mg/kg on Days 30 and 60. Subjects will be followed for 6 months after receiving the last dose of study medication.
Condition Intervention Phase
Cerebral Amyloid Angiopathy Biological: Ponezumab
Other: placebo Phase 2
Estimated Enrollment:36
Study Start Date:April 2013
Estimated Study Completion Date:June 2014
Estimated Primary Completion Date:April 2014 (Final data collection date for primary outcome measure)
http://www.clinicaltrials.gov/ct2/show/NCT01821118?term=ponezumab&rank=5
http://www.cbinet.com/compendiums/PC10188/Presentations/Sprenger_Ken_Presl.pdf
http://www.ncbi.nlm.nih.gov/pubmed/22631613
Pfizer paid $500 million to Renat for two monoclonal antibodies!
"We are encouraged by these data supporting our belief that antibodies targeting soluble forms of A beta can be beneficial in treating AD patients. This idea is consistent with results from the solanezumab Phase 3 clinical trials, which showed a modest but consistent clinical benefit from reducing A beta monomers in the brain. That data has positive implications for the important therapeutic potential of ponezumab, as well of Intellect's internal pipeline of A beta-specific antibodies, including 1A10 (targets the C terminus of A beta at position 40), IC3 (targets the C-terminus of A beta at position 42) and 82E1 (aka IN-N01, targets the N-terminus)," stated Daniel Chain, PhD, chairman and CEO of Intellect. "We have been granted several patents by the USPTO in relation to these antibodies any of which could be developed singly or empowered with additional neuroprotective function under our CONJUMAB platform."
http://globenewswire.com/news-release/2012/11/28/507983/10013867/en/Intellect-Neurosciences-Announces-New-Findings-Supporting-its-Patented-ANTISENILIN-Platform-Technology-for-the-Treatment-of-Alzheimer-s-Disease.html
BUY VOL 540,601
SELL VOL 43,900
Historical Short Selling Data For ILNS
Date VolShorted High Low Close Chg ShortVol RegularVol
Jul 30 80.34% 0.01 0.01 0.01 0.00% 469,601 584,501
http://otcshortreport.com/index.php?index=ilns&action=view#.UfjfZI3WMpk
Num Traded Price Size Type C Exch. Bid Offer Buy Sell ? Buy Ind. Buy Vol. Sell Vol ? Vol.
11 15:28:24 0.0075 3,000 nasd 0.0055 0.0075 3,000
540,601 43,900
10 15:28:00 0.0072 20,000 nasd 0.0055 0.0075 20,000
537,601 43,900
9 12:57:11 0.0075 125,000 nasd 0.0055 0.0075 125,000
517,601 43,900
8 12:24:21 0.0079 40,000 nasd 0.0055 0.0079 40,000
392,601 43,900
7 12:12:45 0.0079 60,000 nasd 0.0055 0.0079 60,000
352,601 43,900
6 12:02:24 0.007 47,000 nasd 0.0055 0.0079 47,000
292,601 43,900
5 12:00:23 0.007 43,900 nasd 0.007 0.0079 43,900
245,601 43,900
4 11:43:21 0.0079 4,000 nasd 0.007 0.0079 4,000
245,601
3 11:34:50 0.007 144,001 nasd 0.0055 0.007 144,001
241,601
2 11:27:31 0.0069 95,600 nasd 0.0055 0.007 95,600
97,600
1 09:32:22 0.0069 2,000 nasd 0.0055 0.0069 2,000
2,000
He's back.....
[ILNS] Intellect Neurosciences Retains Chain Pharmaceuticals LLC
NEW YORK, July 30, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.
"We are delighted Dr. Daniel Chain has agreed to return to Intellect as a consultant and assist us with our strategic options," said Elliot M. Maza, Consulting Chief Financial Officer and Director of Intellect Neurosciences. "As the founder of Intellect, Dr. Chain is uniquely qualified to assist us in our efforts to maximize the value of Intellect's unique collection of high value assets."
http://finance.yahoo.com/news/intellect-neurosciences-retains-chain-pharmaceuticals-153000033.html
A STORM IS COMING
[ILNS] Intellect Neurosciences Retains Chain Pharmaceuticals LLC
NEW YORK, July 30, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.
"We are delighted Dr. Daniel Chain has agreed to return to Intellect as a consultant and assist us with our strategic options," said Elliot M. Maza, Consulting Chief Financial Officer and Director of Intellect Neurosciences. "As the founder of Intellect, Dr. Chain is uniquely qualified to assist us in our efforts to maximize the value of Intellect's unique collection of high value assets."
http://finance.yahoo.com/news/intellect-neurosciences-retains-chain-pharmaceuticals-153000033.html
A STORM IS COMING
[ILNS] Intellect Neurosciences Retains Chain Pharmaceuticals LLC
NEW YORK, July 30, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (ILNS) announced today it has retained Chain Pharmaceuticals LLC as a consultant to assist the company in managing its patent estate and external collaborations and pursuing strategic alternatives for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.
"We are delighted Dr. Daniel Chain has agreed to return to Intellect as a consultant and assist us with our strategic options," said Elliot M. Maza, Consulting Chief Financial Officer and Director of Intellect Neurosciences. "As the founder of Intellect, Dr. Chain is uniquely qualified to assist us in our efforts to maximize the value of Intellect's unique collection of high value assets."
http://finance.yahoo.com/news/intellect-neurosciences-retains-chain-pharmaceuticals-153000033.html
A STORM IS COMING
Expecting a HOT week with FACTS
Hey Fa$tlane, what do you think about $ILNS
$ILNS vs. PFE
VPHM/ILNS - $120 mm deal
Go ILNS
VPHM/ILNS - $120 mm deal
ILNS vs. PFE
Go ILNS
Expecting TauC3 results soon
I have to agree, so keep cool and relax
We will see...hold strong
Hey Johnny
You've got mail ;)
Okay, and then he will buy VPHM or PFE LoL
http://www.chiesigroup.com/web/guest/area-stampa/news/-/journal_articles_esc/EXT_JOURNALARTICLES_ESC_GT_INSTANCE_Tq9y/10129/144970/1.0
$ILNS vs. PFE
Thanks bucki
That's the question... it could happen every day.
Still waiting for TauC3 results
"Recently, Dr. LaFerla's group at UCI completed the animal testing and currently is accumulating the data and preparing a report describing the results of the experiments. We intend to share those results with you promptly upon receipt. Several pharmaceutical companies have expressed interest in our TauC3 program as it represents a first in class and novel alternative therapeutic treatment for AD."
ILNS
You are welcome - ILNS
IBOX has been updated
Look at the BUY, SELL and SHORT volume
Nature Biotechnology 24, 595 - 596 (2006)
Published online: 2 June 2006 | doi:10.1038/nbt0606-595
Monoclonals expand into neural disorders
Brian Vastag1
Washington, D.C.
In April, Pfizer bought a Genentech spinoff, Rinat Neuroscience, for close to five hundred million dollars
Monoclonal antibodies are now being tested to treat ailments of the central nervous system, a new territory for this class of drugs.
In April, Pfizer bought a Genentech spinoff, Rinat Neuroscience, for “close to $500 million dollars,” according to one source. What drew Pfizer's interest to Rinat was its pipeline, in particular, two of its most advanced drugs. Both are monoclonal antibodies that Pfizer hopes to cash in on over the next several years. The deal demonstrates the increased interest in monoclonals in new indications, such as central nervous system (CNS) disorders.
David Pritchard, Rinat's chief business officer, says the S. San Francisco-based company offered its portfolio to eight large drug makers—and received nine offers. “The amount of interest was overwhelming,” he says, and Pfizer's offer topped the list.
Pfizer was drawn to Rinat's two top candidates. The first, coded RN624, treats pain by shutting down nerve growth factor (NGF). It demonstrated impressive early trial results in osteoarthritis patients in the third quarter of 2005 and is now in phase 2 clinical trials. RN624 drew interest because NGF “is the first new clinically validated pain target these companies have seen in decades,” points out Pritchard. The second antibody, RN1219, clears Alzheimer-causing plaque from the brains of mice, but has yet to enter human trials. “Half a billion seems a little high,” says Casey Lynch, managing partner at biotech investment advisor NeuroInsights. “But Pfizer has lots of money in the bank and their pipeline is running dry.”
Rinat's product 'is the first new clinically-validated pain target these companies have seen in decades.'
David Pritchard
Chief Financial Officer of Rinat Neuroscience
Although only one monoclonal antibody for a CNS application (Biogen-Idec's ill-fated multiple sclerosis treatment Tysabri; natalizumab) has been approved by the US Food and Drug Administration to date, the acquisition epitomizes growing excitement in applications of biotech in the 'neuro' area. A recent analysis of 450 companies by San Francisco, California-based consultants NeuroInsights concludes that the worldwide market for neurological disease treatments was $93 million in 2005, a 7% increase over 2004. A quarter of all life sciences venture capital invested in the US now flows into firms in this area. And NeuroInsights 'neurotech' index, which tracks 30 publicly traded companies with this focus, is up 85% since 2004, whereas the NASDAQ and Standard & Poor's 500 are up just 16%.
Pfizer was interested in the quality of Rinat's pipeline, despite its early stage. Rinat's RN624 is now in a phase 2 trial in 300 patients, with full results expected in the second half of 2007. “It does appear to be first in class,” Lynch says of RN624. “It's a good application for an antibody because it targets peripheral cells. It doesn't have to cross the blood-brain barrier.”
The mechanism of action of RN624 is quite complex, however. In embryos, NGF spurs neurodevelopment. But in adults, NGF's only role, apparently, is to drive acute and chronic pain in at least three different ways. “We know it works locally—at the site of injuries and so on—and immediately increases the sensitivity of pain-sensing neurons,” says David Shelton, who began development of RN624 at Genentech in the mid-1990s and is now senior director for biology at Rinat. Second, NGF induces immune mast cells to release inflammatory proteins. Third, NGF drives a feedback loop that upregulates the synthesis of substance P and other pain-related peptides, thereby “increasing pain signaling up the spinal cord,” explains Shelton.
By binding to NGF, RN624 prevents it from latching onto nerve cells. In mouse models, this action dampens incisional, visceral, neuropathic and metastatic bone disease pain. Clinical data released in early May at the American Society of Pain meeting in San Antonio, Texas, show that RN624 effectively reduces osteoarthritis knee pain after a single injection. “It's an unbelievably clean [safety] profile,” says Shelton. “Knock on wood.”
Half a billion seems a little high, but Pfizer has lots of money in the bank and their pipeline is running dry.
Casey Lynch
NeuroInsights
As for competition, Amgen is the only other company with an anti-NGF antibody in phase 1 clinical trials. Originally developed for neuropathic pain, AG403 is now being tested against osteoarthritis pain, too. “They'll keep us on our toes,” remarks Shelton.
Rinat's Alzheimer antibody faces stiffer competition. It has yet to enter clinical trials and at least two dozen companies are also pursuing immunotherapies for Alzheimer. Most use active immunization, in which a small part of the beta-amyloid plaque is injected in hopes that it will recruit the immune system to attack disease-causing brain plaques. Rinat's RN1219 dodges the vagaries of the immune system by directly injecting an anti-plaque antibody. At least two other companies, Eli Lilly, of Indianapolis, Indiana, and the San Diego subsidiary of Elan Pharmaceuticals, of Dublin, are also pursuing so-called passive immunization against Alzheimer; both have antibodies in early clinical trials.
Elan generated a buzz in April when it released early clinical data from 30 patients receiving its monoclonal antibody bapineuzumab. The ten patients receiving the second of three doses showed statistically significant improvement in the mini-mental state examination 16 weeks after antibody injection. However, MRI scans of three of ten patients receiving the highest dose showed abnormalities that could indicate microhemorrhaging, says Dave Morgan, director of the Alzheimer research laboratory at the University of South Florida, Tampa. Morgan, who has no financial stake in Rinat or any other company, was stunned when he saw Elan's data, because he had published several articles showing small brain bleeds in mice receiving Rinat's antibody. “The human data parallels the mouse data perfectly,” he says. “When I first saw [microhemorrhaging] in my mice, I said, 'This is dead, this approach is over.' I was afraid Rinat was going to call me a lousy scientist. Instead, they wanted to see if they could correct it.”
Rinat cofounder and president, Arnon Ronsenthal, thought that a modified version of the antibody, one that didn't bind to glucose, might provide a cleaner safety profile. His team engineered such an antibody and shipped it to Morgan for mouse testing. In the May 17 issue of the Journal of Neuroscience (2006, 26 (20): 5340–5346), Morgan's team reports that the new, deglycosylated antibody clears beta-amyloid plaque as well as or better than the older antibody while causing less microhemorrhaging. The mice also performed better on a standard water-maze memory test.
Elan and others in the field are now eager to develop their own deglycosylated antibodies. But the standard method of deglycosylation uses a slow, expensive enzyme reaction. Here, Rinat has a head start—its latest antibody lacks the glucose-reaction site altogether. “They engineered it that way,” says Morgan. Citing confidentiality concerns, Rosenthal would not confirm this, but he did say that Rinat's antibody is “specifically designed to minimize” microhemorrhaging.
As for sneaking an antibody across the blood-brain barrier, no one can say for certain how the anti-Alzheimer antibodies manage the trick. Theories abound, but Rosenthal believes that, whatever, the mechanism, clinical data will drive the field. He says the company's first Alzheimer trial will begin this summer, although the company and its new owner are still debating whether to run it in Europe, Australia or the United States.
http://www.nature.com/nbt/journal/v24/n6/full/nbt0606-595.html
STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL
USAN PONEZUMAB
PRONUNCIATION poe nez' oo mab
THERAPEUTIC CLAIM Treatment of Alzheimer’s disease
CHEMICAL NAMES
1. Immunoglobulin G2, anti-(human ß-amyloid) (human-mouse monoclonal PF-04360365
clone 9TL heavy chain), disulfide with human-mouse monoclonal PF-04360365
clone 9TL light chain, dimer
2. Immunoglobulin G2, anti-(human amyloid beta A4 protein (Alzheimer disease amyloid
protein, ABPP, APPI, preA4, protease nexin-II)); humanized mouse monoclonal
PF-04360365 clone 9TL des-442-lysine(CH3107-K)-[325-serine(CH299A>S),326-
serine(CH2100P>S)]?2 heavy chain (130-219')-disulfide with humanized mouse
monoclonal PF-04360365 clone 9TL ? light chain, dimer (218-218'':219-219'':222-
222':225-225'')-tetrakisdisulfide
MOLECULAR FORMULA C6552H10158N1730O2090S52
MOLECULAR WEIGHT 148.3 kDa
TRADEMARK None as yet
MANUFACTURER Pfizer, Inc.
CODE DESIGNATION PF-04360365, RN-1219
CAS REGISTRY NUMBER 1178862-65-1
http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf
http://www.iscd.org/wp-content/uploads/2012/10/PressRelease012609FINAL.pdf
http://www.drugs.com/news/intellect-neurosciences-inc-grants-license-certain-patents-patent-applications-wyeth-elan-pharma-8210.html
http://www.biospace.com/News/intellect-neurosciences-inc-grants-to-top-tier/112397
http://news.bio-medicine.org/?q=medicine-news-1/intellect-neurosciences--inc--grants-to-top-tier-global-pharmaceutical-company-license-to-certain-alzheimers-patents-and-patent-applications-33226